Medicare will continue paying for Avastin, produced by Roche Holding's Genentech unit, as a treatment for breast cancer, even if the FDA decides to revoke its conditional approval, said CMS spokesman Don McLeod.
An FDA advisory committee voted unanimously to remove this indication, though the final decision rests with FDA Commissioner Dr. Margaret Hamburg. "The drug will still be on the market, doctors will still be prescribing it, and we will continue to pay for it," McLeod said.

Full Story:
ABC News

Related Summaries